04 May 2026 : Clinical Research
Recurrence Rate and Survival in 260 Patients With Oncocytic Thyroid Cancer According to Response to Initial Treatment – A Single-Institution Experience
Nikola Besic ABCEG 1*, Barbara Gazic BDEG 2,3DOI: 10.12659/MSM.950937
Med Sci Monit 2026; 32:e950937
Table 2 Factors associated with the length of disease-free survival after the beginning of oncological therapy by univariate and multivariate Cox proportional hazards regression.
| Factor | Univariate | Multivariate* | ||||||
|---|---|---|---|---|---|---|---|---|
| P value | Exp (β) | Exp (β)95% CIlower | Exp (β)95% CIupper | P value | Exp (β) | Exp (β)95% CIlower | Exp (β)95% CIupper | |
| 0.071 | 1.329 | 0.976 | 1.810 | |||||
| N stage (N0) | 0.216 | 2.157 | 0.639 | 7.281 | – | – | – | – |
| Subtype of invasiveness (minimally invasive) | 0.790 | 0.983 | 0.864 | 1.117 | – | – | – | – |
| Thyroid surgery (lobectomy) | 0.746 | 1.016 | 0.925 | 1.115 | – | – | – | – |
| Radioiodine ablation after surgery (no) | 0.133 | 4.622 | 0.627 | 34.077 | – | – | – | – |
| * Variables not included in the multivariate model due to lack of significance (>0.10) on univariate analysis. Exp (β) – hazard ratio; CI – confidence interval; pT tumor stage – pathological primary tumor stage; N stage – regional lymph node stage; ‘−’ – variables not in the multivariate model due to lack of significance (>0.10) on univariate analysis, Minimally invasive – limited vascular invasion ( | ||||||||